Company news

Basilea Pharmaceutica AG news in 2026

Basilea Pharmaceutica AG's news releases, calls and decks from 2026, newest first.

View company

Basilea raises full-year guidance 2026 and financial target for “Agenda 2030” and provides updates on late-stage clinical programs

October 27, 2026

Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026

October 20, 2026

Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients

September 14, 2026

Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track

August 18, 2026

Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

August 5, 2026

Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix

July 29, 2026

Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

May 28, 2026

Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting

April 15, 2026

Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420

April 9, 2026

Basilea announces start of first‑in‑human study of novel antibiotic BAL2420

March 23, 2026

Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

February 25, 2026

Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance

February 17, 2026

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

February 9, 2026

Basilea joins INCATE to support antifungal innovation

January 13, 2026

Basilea provides portfolio update and outlook

January 8, 2026

Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections

January 7, 2026

Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections

January 7, 2026

Calls in 2026

Decks in 2026